Prestige Consumer Healthcare (PBH)

NYSEHealth CareMedical - PharmaceuticalsSnapshot 2026-10-23

$47.80-3.36%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Prestige Consumer Healthcare’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

0.0%

+10% or more+5%0%−5%−10% or less

5.13 → 5.13 EPS · FY ending Mar 31, 2028 · 5 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 5 to 5; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2027 · Q3
Revenue	—	353.1M
EPS	—	1.241
FY 2027 · Annual
Revenue	—	1.3B
EPS	$4.55–$4.65non-GAAP $4.18–$4.28GAAP	4.584
Operating cash flow	$277MGAAP	—
FY 2028 · Annual
Revenue	—	1.38B
EPS	—	5.133

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Revenue near $1.11 billion in fiscal 2027	Revenue is expected near $1.11 billion in fiscal 2027.	Intact	revenue falls below $1.0 billion in FY27	Revenue: $265.71M FY2027-Q1; GAAP. Published target: ~$1.11B. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026265,710,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q1 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 8464633b-bf36-4cbe-a51b-918903ae5750. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2 and a June 2026 announcement. The acquisitions of Breathe Right and LaCorium add nearly 20% to the revenue base, with Breathe Right acquired for $1.045 billion and LaCorium generating $40 million annually. Management raised fiscal 2027 revenue outlook accordingly. The trajectory is delivering with completed acquisitions and revenue contributions. Delivery assessment Oct 24, 2026
Manage debt from acquisitions without hurting financial health	A supporting condition in Prestige Consumer Healthcare's published investment case. The stated target is Maintain manageable debt levels and credit agreements.	Intact	Debt or credit issues impair operations or capital costs rise sharply	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Free cash flow at least $250 million in fiscal 2027	A supporting condition in Prestige Consumer Healthcare's published investment case. The stated target is >=250 million USD.	Intact	free cash flow falls below $200 million in FY27	Free cash flow: $67.085M FY2027-Q1; GAAP. Published target: >=250 million USD. Target period is not explicitly aligned with this observation. Source published Aug 6, 202667,085,000 USD · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q1 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2027-Q1. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Adjusted diluted EPS near $4.46 in fiscal 2027	Revenue is expected near $1.11 billion in fiscal 2027.	Intact	EPS falls below $4.2 in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Management stated this priority in 3 quarters including 2025-Q4, 2026-Q1, and 2026-Q2. Operating income declined from $75.5 million in 2026-Q4 to $52.5 million in 2026-Q2, reflecting some pressure, but adjusted free cash flow increased to $83.7 million in 2026-Q2 from $78.2 million prior year. Management emphasizes momentum and positioning to improve profitability, indicating mixed but ongoing focus. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-03-31 · fmp

FY2028 EPS$5.13

Unavailable → $5.13 · observed estimates

FY2028 revenue$1.38B

Unavailable → $1.38B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	2 / 3
2026-07-25	Unavailable	Unavailable	3 / 3
2026-07-26	Unavailable	Unavailable	3 / 3
2026-07-27	Unavailable	Unavailable	3 / 3
2026-07-28	Unavailable	Unavailable	3 / 3
2026-07-29	Unavailable	Unavailable	3 / 3
2026-07-30	Unavailable	Unavailable	3 / 3
2026-07-31	Unavailable	Unavailable	2 / 3
2026-08-01	Unavailable	Unavailable	2 / 3
2026-08-02	$4.96	Unavailable	5 / 4
2026-08-03	Unavailable	Unavailable	3 / 4
2026-08-04	$4.96	Unavailable	5 / 4
2026-08-05	Unavailable	Unavailable	3 / 4
2026-08-06	Unavailable	Unavailable	3 / 4
2026-08-07	Unavailable	Unavailable	3 / 4
2026-08-08	$5.04	$1,333,351,400	5 / 5
2026-08-09	$5.04	$1,333,351,400	5 / 5
2026-08-10	$5.04	$1,333,351,400	5 / 5
2026-08-12	$5.06	$1,345,385,860	7 / 7
2026-08-13	Unavailable	Unavailable	3 / 4
2026-08-14	Unavailable	Unavailable	3 / 4
2026-08-15	Unavailable	$1,275,216,594	4 / 5
2026-08-16	Unavailable	$1,275,216,594	4 / 5
2026-08-17	Unavailable	$1,275,216,594	4 / 5
2026-08-18	Unavailable	$1,275,216,594	4 / 5
2026-08-19	Unavailable	$1,275,216,594	4 / 5
2026-08-20	$5.13	$1,383,630,386	5 / 6
2026-08-21	$5.13	$1,383,630,386	5 / 6
2026-08-22	$5.13	$1,383,630,386	5 / 6
2026-08-23	$5.13	$1,383,630,386	5 / 6
2026-08-24	$5.13	$1,383,630,386	5 / 6
2026-08-25	$5.13	$1,383,630,386	5 / 6
2026-08-26	$5.13	$1,383,630,386	5 / 6
2026-08-27	$5.13	$1,383,630,386	5 / 6
2026-08-28	$5.13	$1,383,630,386	5 / 6
2026-08-29	$5.13	$1,383,630,386	5 / 6
2026-08-30	$5.13	$1,383,630,386	5 / 6
2026-08-31	$5.13	$1,383,630,386	5 / 6
2026-09-01	$5.13	$1,383,630,386	5 / 6
2026-09-02	$5.13	$1,383,630,386	5 / 6
2026-09-03	$5.13	$1,383,630,386	5 / 6
2026-09-04	$5.13	$1,383,630,386	5 / 6
2026-09-05	$5.13	$1,383,630,386	5 / 6
2026-09-06	$5.13	$1,383,630,386	5 / 6
2026-09-07	$5.13	$1,383,630,386	5 / 6
2026-09-08	$5.13	$1,383,630,386	5 / 6
2026-09-09	$5.13	$1,383,630,386	5 / 6
2026-09-10	$5.13	$1,383,630,386	5 / 6
2026-09-11	$5.13	$1,383,630,386	5 / 6
2026-09-12	$5.13	$1,383,630,386	5 / 6
2026-09-13	$5.13	$1,383,630,386	5 / 6
2026-09-14	$5.13	$1,383,630,386	5 / 6
2026-09-15	$5.13	$1,383,630,386	5 / 6
2026-09-16	$5.13	$1,383,630,386	5 / 6
2026-09-17	$5.13	$1,383,630,386	5 / 6
2026-09-18	$5.13	$1,383,630,386	5 / 6
2026-09-19	$5.13	$1,383,630,386	5 / 6
2026-09-20	$5.13	$1,383,630,386	5 / 6
2026-09-21	$5.13	$1,383,630,386	5 / 6
2026-09-22	$5.13	$1,383,630,386	5 / 6
2026-09-23	$5.13	$1,383,630,386	5 / 6
2026-09-24	$5.13	$1,383,630,386	5 / 6
2026-09-25	$5.13	$1,383,630,386	5 / 6
2026-09-26	$5.13	$1,383,630,386	5 / 6
2026-09-27	$5.13	$1,383,630,386	5 / 6
2026-09-28	$5.13	$1,383,630,386	5 / 6
2026-09-29	$5.13	$1,383,630,386	5 / 6
2026-09-30	$5.13	$1,383,630,386	5 / 6
2026-10-01	$5.13	$1,383,630,386	5 / 6
2026-10-02	$5.13	$1,383,630,386	5 / 6
2026-10-03	$5.13	$1,383,630,386	5 / 6
2026-10-04	$5.13	$1,383,630,386	5 / 6
2026-10-05	$5.13	$1,383,630,386	5 / 6
2026-10-06	$5.13	$1,383,630,386	5 / 6
2026-10-07	$5.13	$1,383,630,386	5 / 6
2026-10-08	$5.13	$1,383,630,386	5 / 6
2026-10-09	$5.13	$1,383,630,386	5 / 6
2026-10-10	$5.13	$1,383,630,386	5 / 6
2026-10-11	$5.13	$1,383,630,386	5 / 6
2026-10-12	$5.13	$1,383,630,386	5 / 6
2026-10-13	$5.13	$1,383,630,386	5 / 6
2026-10-14	$5.13	$1,383,630,386	5 / 6
2026-10-15	$5.13	$1,383,630,386	5 / 6
2026-10-16	$5.13	$1,383,630,386	5 / 6
2026-10-17	$5.13	$1,383,630,386	5 / 6
2026-10-18	$5.13	$1,383,630,386	5 / 6
2026-10-19	$5.13	$1,383,630,386	5 / 6
2026-10-20	$5.13	$1,383,630,386	5 / 6
2026-10-21	$5.13	$1,383,630,386	5 / 6
2026-10-22	$5.13	$1,383,630,386	5 / 6
2026-10-23	$5.13	$1,383,630,386	5 / 6
2026-10-24	$5.13	$1,383,630,386	5 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	7	2
2026-06-01	5	2
2026-07-01	6	2
2026-08-01	5	2
2026-09-01	5	2
2026-10-01	5	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 5 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Revenue near $1.11 billion in fiscal 2027Revenue: $265.71M
Manage debt from acquisitions without hurting financial healthQualitative condition
Free cash flow at least $250 million in fiscal 2027Free cash flow: $67.085M
Adjusted diluted EPS near $4.46 in fiscal 2027Direct metric needs a verified mapping

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.6%Typical daily move · historical

Downside history

-36.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Prestige Consumer Healthcare outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

PBH is an acquisition-led healthcare business with a mixed execution record, rather than a simple steady-growth story. Its multi-year view is intact, though the recent signal has softened from favorable to mildly favorable.

What's priced into Prestige Consumer Healthcare

The evidence describes PBH as cheap versus peers, with a negative expectations gap, meaning expectations appear lower than the valuation model’s view of the business. Pricing is tagged as justified, and no fragility concerns were flagged.

What the fundamentals likely do

Near-term results have been strong overall, and management raised its fiscal 2027 revenue outlook after acquisitions added nearly 20% to the revenue base. Profitability remains mixed: operating income declined, while adjusted free cash flow increased. Recent earnings misses and a downward trend in earnings surprises temper the otherwise strong picture.

What Prestige Consumer Healthcare hinges on

Over the next few quarters, a reversal of recently raised guidance would damage management credibility. A further weakening in job growth could also raise recession concerns for cyclical healthcare names, while continued strength among sector peers could support the broader backdrop. Over the multi-year view, the key test is whether acquisitions translate into better operating income while free cash flow stays strong.